Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease
The Road Ahead: Future Prospects of GLP-1 Agonists The future of GLP-1 agonists appears promising, with ongoing research aimed at enhancing their efficacy while minimizing side effects
Even with a letter of medical necessity, most administrators will still deny reimbursement
Hopefully I can just continue keeping this weight off, Deborah Finley, 50, of Lodi said
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Less Food = Less Fluid Many people eat less when taking GLP-1s, which also means theyre consuming fewer hydrating foods, such as fruits, vegetables, and soups
